Skip to main content

Table 1 Main characteristics of all the included studies

From: Recombinant human adenovirus-p53 therapy for the treatment of nasopharyngeal carcinoma: a meta-analysis

Studies

RAd-p53

RT

CT

Stages

Jadad

Qin et al. (2012)

1 × 1012 VP

1 time/week/6–7 weeks

Nasopharynx: 70–76 Gy/35–38f

Neck: 66–70 Gy

Carboplatin: 500 mg/m2

Fluorouracil: 2000 mg/m2

III–IV

2

Lan et al. (2011)

1 × 1012 VP

1 time/week/6–8 weeks

Nasopharynx: 70–76 Gy/35f

Neck: 60–70 Gy

Carboplatin: 500 mg/m2

5-Fluorouracil: 2000 mg/m2

III–IV

2

Wang et al. (2010)

1 × 1012 VP

Saline dilution 2–4 ml

Nasopharynx: 70 Gy/35f

Neck: 70 Gy/35f

III–IV

2

Li (2012)

1 × 1012 VP

Nasopharynx: 70–76 Gy/7–8 weeks

Neck: 60–70 Gy

Carboplatin: 300–500 mg/m2

5-Fluorouracil: 300–500 mg/m2

III–IV

2

Chen et al. (2003)

1 × 1012 VP

1 time/week/8 weeks

Nasopharynx: 70–76 Gy/7–8 weeks

Neck: 60–70 Gy/7–8 weeks

II–IV

2

Si et al. (2009)

1 × 1012 VP

1 time/week/6–8 weeks

Nasopharynx: 70–76 Gy/7–8 weeks

Neck: 36 Gy/4 weeks

60–70 Gy/3–4 weeks

Carboplatin: 300–500 mg/m2

5-Fluorouracil: 300–500 mg/m2

III–IV

3

Wang et al. (2012)

1 × 1012 VP

1 time/week/9–10 weeks

Nasopharynx: 66–70 Gy/35f

Neck: 66–70 Gy/35f

I–III

2

Zhang et al. (2006)

1 × 1012 VP

1 time/week/8 weeks

Nasopharynx: 70 Gy/35f

Neck: 70 Gy/35f

Unclear

3

Zhang et al. (2011)

2 × 1012 VP

1 time/week/6 weeks

68–76 Gy to 60–70 Gy/6 weeks

Cisplatin: 75 mg/m2

Paclitaxel: 75 mg/m2

III–IV

3

Pan et al. (2009)

1 × 1012 VP

1time/week/8 weeks

Nasopharynx: 70 Gy/35f

Neck: 70 Gy/35f

II–IV

3

Lan et al. (2012)

1 × 1012 VP

1 time/3 days/6–8 times

70–76 Gy/35–38f

Cisplatin: 300 mg/m2

5-Fluorouracil: 2000 mg/m2

Unclear

2

Zhang et al. (2007)

1 × 1012 VP

1 time/1 week/8 times

Nasopharynx: 70 Gy/35f

Neck: 70 Gy/35f

Unclear

3

  1. RAd-p53 recombinant human adenovirus-p53 injection; RT radiotherapy; CT chemotherapy